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Introduction: Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early
breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to
hormone receptor status of the primary tumor have not been described.
Methods: Using data from 1,260 patients randomized to placebo in the adjuvant TEACH trial, we report 10-year
annual hazards of recurrence in HER2+ patients not treated with anti-HER2 therapy.
Results: Disease-free survival (DFS) was 75% after 5 and 61% after 10 years, respectively. Patients with HER2+
hormone receptor-positive (HR+ (hormone receptor-positive); ER+ (estrogen receptor-positive) or PR+ (progesterone
receptor-positive)) disease had a significantly better DFS than patients with HER2+ HR- (ER-/PR-) disease (hazard
ratio 0.72, P = 0.02). This difference was explainable by a significantly higher hazard of recurrence in years 1 to 5 in
HER2+ HR- compared to HER2+ HR+ patients, with a mean risk of recurrence of 9%/year for HR- versus 5%/year in
HR+ patients (hazard ratio 0.59, P = 0.002 for years 1 to 5). The high early risk of recurrence of HER2+ HR- patients
declined sharply over time, so that it was similar to that seen in HER2+ HR+ patients in years 6 to 10 (hazard ratio
0.97, P = 0.92 for years 6 to 10).
Conclusions: Our results show that outcomes in HER2+ patients with early BC not receiving anti-HER2 therapy
strongly depend on HR expression. The very high early risk of relapse seen in HER2+ HR- patients is particularly
relevant in health care settings with limited access to adjuvant anti-HER2 treatment. The event rates shown for
subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2+ HR-
early BC should be prioritized for consideration of adjuvant anti-HER2 therapy.Introduction
Standard adjuvant treatment of localized high-risk human
epidermal growth factor receptor 2-positive (HER2+) early
breast cancer (BC) substantially reduces the risk of disease
recurrence and improves survival [1]. Current standard
systemic treatment consists of chemotherapy with one
year of trastuzumab, a monoclonal antibody targeting the
HER2 extracellular domain. In resource-limited countries
or populations, access to trastuzumab is often limited by
economic or logistic conditions [2].* Correspondence: pgoss@partners.org
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article, unless otherwise stated.Cancer outcomes in this common setting of having re-
ceived chemotherapy +/− endocrine therapy but not
trastuzumab have not been fully described.
We report here the annual hazards of recurrence
based on hormone receptor (HR) status among patients
with HER2+ early BC treated with chemotherapy +/−
endocrine therapy but not with anti-HER2 therapy.
Methods
Study design and participants
Our analyses are based on data from the placebo arm
of the adjuvant Tykerb evaluation after chemotherapy
(TEACH) trial (ClinicalTrials.gov number NCT00374322),
the design and main outcomes of which have been previ-
ously published [3]. Briefly, between August 2006 and
May 2008, the study recruited 3,161 women with stage ICentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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mors were ≥1 cm) HER2+ invasive BC who were disease-
free at any time in follow-up after completion of prior
adjuvant chemotherapy, but who had not received adju-
vant trastuzumab. By randomizing patients at any time
after diagnosis, the design of this trial and the resulting co-
hort of patients included are unique, as patients as late as
179 months from diagnosis were randomized (analysis ac-
counts for left-truncation), resulting in a very long follow-
up period from diagnosis.
The study was approved by ethics review boards at all
participating centers (see Additional file 1). Patients gave
written, informed consent. The study complied with the
Declaration of Helsinki and Good Clinical Practice. Only
patients assigned to the placebo group and with centrally
confirmed (positive by fluorescence in situ hybridization)
HER2+ disease (n = 1,260 of 1,576 in the placebo arm)
are included in this analysis.
Patients were randomized to oral lapatinib or placebo,
daily for 12 months or until disease recurrence, develop-
ment of a second primary cancer, or unacceptable tox-
icity. Details of randomization and stratification have
been previously published [3].
Procedures
Patients were followed every 3 months up until 2 years
from diagnosis if they had been randomized within
2 years from diagnosis, once every 6 months up until
5 years from diagnosis if they had been randomized be-
tween 2 and 5 years from diagnosis and yearly once they
were >5 years from diagnosis. The disease-free survival
(DFS) events in this analysis were defined as in the pri-
mary analysis [3].
Statistical analysis
DFS is measured from the date of diagnosis (not the
date of randomization). Patients on TEACH had to have
had a minimum time from diagnosis to randomization
of 3 months. Thus, since patients entered TEACH
between 3 and 179 months after diagnosis (median:
32 months), the DFS times from primary diagnosis of
BC are left-truncated for all patients; that is, patients
included in this analysis had to have survived and
remained disease-free long enough to enter TEACH. In
addition, DFS times are right-censored for the 1,045 pa-
tients who remained disease-free at the conclusion of
follow-up. To account for the left-truncation, patients
were included in the risk set for a DFS failure at the time
they entered the trial (measured from time of diagnosis)
[4]. After the time patients had an event or were cen-
sored, they were excluded from the risk set calculations.
Thus we obtained unbiased estimates of recurrence risk
starting at 3 months post diagnosis, with the precision
of the estimates increasing (and then decreasing) withtime since diagnosis as more patients enter the trial (and
then leave the trial).
The Kaplan-Meier method was used to estimate the
empirical distribution of DFS from diagnosis, overall and
by HR subgroups. The annual hazard function, giving
the risk of disease at a specified time conditional on
remaining disease-free up until that point in time, was
estimated overall and by HR status using splines with
separate splines fit for the cohort overall and by HR sta-
tus [5]. The number of knots used for the splines was
determined by comparing the Akaike information criter-
ion (AIC) model fit statistics for a range of choices for
number of knots and choosing the value that minimized
the AIC statistic, which penalizes models with more
knots to avoid overfitting [6]. Cox proportional hazards
models were used to evaluate risk of DFS events by
prognostic factors. These models rely on the assumption
that the effect of a prognostic factor on risk of recur-
rence remains constant over time. As previous data have
consistently shown time-varying hazards of recurrence
by ER status in HER2-untested cohorts [7-9] potential vio-
lations of this assumption for each prognostic factor were
evaluated by examining smoothed plots of the scaled
Schoenfeld residuals over time and testing for an associ-
ation between the residuals and time via regression [10].
Results
Overall, 1,260 patients assigned to placebo and with cen-
trally confirmed HER2+ disease were included in the
analysis. A total of 55.5% (N = 699) had hormone recep-
tor positive (HR+, estrogen (ER) and/or progesterone
receptor (PR)-positive) disease, and 44.5% (N = 561) HR-
negative disease (HR-, ER and PR-negative disease).
Clinical characteristics are shown in Table 1. Median
time from diagnosis to randomization was 32 (3 to 179)
months and median follow-up from randomization was
42 (0 to 60) months. The resulting median time from
diagnosis to last follow-up was 70 (9 to 216) months.
In all centrally confirmed HER2+ placebo patients 5-
year DFS was 75% and 10-year DFS was 61%. Figure 1
shows the hazard of recurrence for centrally confirmed
HER2+ placebo patients. We were able to calculate the
curve starting at 3 months post diagnosis, as this was
the shortest time between diagnosis and trial entry. As
more patients entered the trial, the confidence interval
narrows, and widens again as the patient population at
risk declines due to disease-free events and censoring.
The annual hazard of recurrence for HER2+ patients not
treated with anti-HER2 therapy was initially approxi-
mately 10% per year, dropping rapidly in years 1 to 5
and stabilizing at an ongoing risk of recurrence of about
3.5% per year at 6 to 10 years post diagnosis.
Analysis of DFS according to HR status showed a su-
perior outcome for patients with HR+ (ER+ and/or PR+)
Table 1 Baseline clinical characteristics of placebo




(N = 1,260) (N = 561) (N = 699)
Median age, yrs (range) 50 (22–81) 51 (24–81) 48 (22–80)
Age range (%)
<40 217 (17) 78 (14) 139 (20)
40-50 446 (36) 160 (28) 286 (41)
50-60 414 (33) 224 (40) 190 (27)
60-70 155 (12) 83 (15) 72 (10)
>70 28 (2) 16 (3) 12 (2)
Postmenopausal, n (%) 854 (68) 403 (72) 451 (65)
Race, n (%)
White 840 (67) 370 (66) 470 (67)
Asian 298 (23) 135 (24) 163 (23)
Black 35 (3) 16 (3) 19 (3)
Other/unknown 87 (7) 40 (7) 47 (7)
Median time since initial
diagnosis, yrs (range)
3 (0–15) 2 (0–15) 3 (0–12)
Years since initial diagnosis,
n (%)
≤4 916 (73) 430 (77) 486 (70)
>4 344 (27) 131 (23) 213 (30)
0-1 278 (22) 138 (25) 140 (20)
Hormone receptor status, n (%)
HR+ (ER+ or PR+) 695 (55) - 695 (100)
ER+ and PR+ 438 (35) - 438 (63)
ER+ and PR- 170 (13) - 170 (24)
ER- and PR+ 87 (7) - 87 (13)
HR- (ER- and PR-) 561 (45) 561 (100) -
Nodal involvement, n (%) 698 (57) 303 (55) 395 (58)
Low stage (T1 N0), n (%) 220 (18) 92 (17) 128 (19)
Prior or concurrent endocrine
therapy (HR+ only), n (%)
Yes 625 (50) - 625 (89)
No 74 (6) - 74 (11)
N/A 561 (45) 561 (100) -
Adjuvant chemotherapy, n (%)
Anthracycline without taxane 710 (56) 303 (54) 407 (58)
Anthracycline with taxane 503 (40) 234 (42) 269 (39)
No anthracycline 47 (4) 24 (4) 23 (3)
HER2+, human epidermal growth factor receptor 2 positive; TEACH, Tykerb
evaluation after chemotherapy; HR+, hormone receptor positive; ER+, estrogen
receptor positive; PR+, progesterone receptor positive; ER-, estrogen receptor
negative; HR-, hormone receptor negative; PR-, progesterone receptor negative.
Figure 1 Annual hazard of disease recurrence in centrally confirmed
HER2+ placebo patients in TEACH. HER2+, human epidermal growth
factor receptor 2 positive; TEACH, Tykerb evaluation after chemotherapy.
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HR- (ER-/PR-) cohort (hazard ratio 0.72, P = 0.02).
The annual hazards of disease recurrence of centrally
confirmed HER2+ patients by HR status are presented
in Figure 2a, showing that the high hazard of recurrence
in the overall cohort is almost exclusively attributed to pa-
tients with HR- disease. In addition, it can be seen that
while HR+ patients have a relatively constant annual haz-
ard of recurrence over time, HR- patients experience high
annual hazards of recurrence early on, with a steep de-
crease over the first 5 to 6 years after diagnosis. The mean
annual hazards of recurrence in years 1 to 5 from diag-
nosis were 9% versus 5% in HR- versus HR+ patients,
respectively. In years 6 to 10, the annual hazards of re-
currence were very similar between HR- and HR+ pa-
tients (mean hazard 4% in both groups).
The time-dependent hazard ratio for patients with HR+
versus HR- disease is given in Figure 2b. As suggested by
the nonparallel hazard curves for HR+ versus HR- disease
in Figure 2a, the test of the proportional hazards assump-
tion was rejected indicating a nonconstant hazard ratio
(P = 0.05). The analysis confirms a time dependence of
the hazard ratio by HR status in HER2+ patients, indicat-
ing that the fixed hazard ratio of 0.72 over 10 years
underestimates the difference between the HR+ and
HR- groups in the first years after diagnosis. The hazard
ratios from a Cox model stratified by time are 0.64 for
years 1 to 5 and 0.93 for years 6 to 10, showing that the
risk of early relapse is substantially higher for HER2+
HR- than for HER2+ HR+ patients.
Figure 2 Annual hazards and time-dependent hazard ratio for disease recurrence in centrally confirmed HER2+ patients by HR status. (a) Annual
hazard of disease recurrence in centrally confirmed HER2+ placebo patients in TEACH, according to HR status (95% confidence limits at 2-year
intervals). (HR+ = ER+ and/or PR+; HR- = ER- and PR-). (b) Hazard ratio for disease recurrence in centrally confirmed HER2+ placebo patients in
TEACH, comparing HR+ versus HR-. (HR+ = ER+ and/or PR+; HR- = ER- and PR-). ER-, estrogen receptor negative; ER+, estrogen receptor positive;
HER2+, human epidermal growth factor receptor 2 positive; HR-, hormone receptor negative; HR+, hormone receptor positive; PR-, progesterone
receptor negative; PR+, progesterone receptor positive; TEACH, Tykerb evaluation after chemotherapy.
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for risk of recurrence, taking into account prognostic
factors. Since tests of the proportional hazards assump-
tion indicated nonconstant hazards for ER+ status in
addition to HR+ status, hazard ratios are reported separ-
ately for years 1 to 5 and 6 to 10 post diagnosis. For the
other prognostic factors in Table 2, the proportional haz-
ards assumption was not violated. Patients <40 years at
diagnosis had a worse prognosis, but this effect was only
marginally statistically significant and not seen when dif-
ferent cutoffs for age (50, 60) were used. As expected,
low tumor stage and negative nodes were significant
prognosticators, each reducing recurrence risk by ap-
proximately 50% (hazard ratio 0.42 (0.26 to 0.69) and
0.52 (0.39 to 0.7), respectively). The additional use of
taxane-based chemotherapy did not improve the prog-
nosis of patients who were treated with anthracyclines
(hazard ratio 1.06 (0.81 to 1.40)), and no difference was
seen based on whether patients were treated with or
without anthracyclines (hazard ratio 0.95 (0.47 to 1.94)).
However, only few patients were treated without anthra-
cyclines (N = 47).
Multivariable analysis of prognostic factors confirmed
the significant influence of HR status and nodal status
on risk of recurrence, whereas age at diagnosis as well as
low stage were only marginally statistically significant
(Table 2).
Discussion
Our results confirm that HER2+ BC patients untreated
with anti-HER2 therapy have a high risk of recurrence,particularly during years 1 to 5 post diagnosis. The an-
nual hazard for recurrence in patients with tumors at
least 1 cm in size starts at about 10% per year, decreases
over time, and stabilizes at about 4% per year after 6 to
8 years. After 10 years approximately 40% of patients
will have experienced a recurrence.
From previous data in HER2-untested cohorts [7-9,11,12],
reporting that HR expression exhibits time-dependent
nonproportional hazard effects on prognosis [8,9], it was
unclear whether these effects would also be present in
HER2+ patients, which have likely been a minority within
the previously studied cohorts. Our results are novel, as
we show that a difference in the hazard of recurrence be-
tween HR+ and HR- patients is evident in HER2+ patients
treated with modern chemotherapy and endocrine therapy
but not with anti-HER2 therapy. HER2+HR- patients
have an average yearly rate of recurrence of 9% in years 1
to 5 compared to an average of 5% for HER2+HR+ pa-
tients. HR expression is thus an important determinant of
long-term outcome in HER2+ patients not treated with
anti-HER2 therapy.
Apart from a difference in the mean hazard of recur-
rence, we also show that the shapes of the hazard curves
differ significantly between HER2+ HR+ and HER2- HR-
patients. By showing that there are indeed fundamental
differences in the behavior of HR- and HR+ HER2+ BC
(with the time-dependent hazard ratio crossing 1) and
providing the hazard functions for each group over time,
our data will allow correct up-to-date estimates of abso-
lute treatment effects for clinical trials of future novel
therapies in HER2+ patients.
Figure 3 Univariable hazard ratios for risk of disease recurrence by prognostic factors in centrally confirmed HER2+ placebo patients in TEACH.
HER2+, human epidermal growth factor receptor 2 positive; TEACH, Tykerb evaluation after chemotherapy.
Strasser-Weippl et al. Breast Cancer Research  (2015) 17:56 Page 5 of 7In an indirect way, our data also allow inferences
about the effect of endocrine therapy in HER2+ BC pa-
tients not treated with anti-HER2 therapy: it would have
been possible that the flattening effect of endocrine ther-
apy on the early hazard of recurrence of HR+ patients
that was seen in HER2-unknown (that is mostly HER2-)
cohorts [8,9,11] is not seen if the HER2 epitope is not
targeted as well, thus resulting in a similar early peak in
HER2+ HR+ patients as seen in HER2+ HR- patients. It
is therefore important to note that the reduction in the
early hazard of recurrence achieved by endocrine ther-
apy in ER+ patients (with unknown HER2 status) seems
to still be evident in HER2+HR+ patients, underlining
the importance of effective endocrine treatment, includ-
ing prolonged therapy, in these patients even when anti-
HER2 therapy administration is not possible.
Subgroup analyses showed that the risk of recurrence
was not significantly influenced by menopausal status or
age. However, lymph node involvement and higher tumor
stage were each associated with significant increases in therisk for disease recurrence, underlining the importance of
tumor stage for the prognosis of HER2+ BC patients.
Based on our data, HR expression can thus be used -
in addition to tumor stage - in HER2+ patients to iden-
tify those at the highest risk. As the relative effect of
trastuzumab is similar in patients with HR+ and HR-
disease [13-15] the absolute benefit of treatment with
trastuzumab is based on a patient’s absolute baseline
risk. Therefore, by reporting that trastuzumab-naïve
HER2+ HR- patients have a substantially higher recur-
rence rate than HER2+ HR+ patients, we infer and show
that HER2+ HR- will derive higher absolute treatment
benefits from trastuzumab treatment. Many countries
worldwide with limited resources currently opt not to
provide adjuvant trastuzumab at all because of economic
reasons. Irrespective of the ultimate goal to provide ad-
juvant anti-HER2 therapy to all HER2+ patients as de-
fined in the adjuvant trials, our data might therefore
provide a strong rationale for offering anti-HER2 therapy
to HER2+ HR- subpopulations.
Table 2 Multivariable hazard ratios for risk of disease
recurrence by prognostic factors in centrally confirmed
HER2+ placebo patients in TEACH
Prognostic factor Hazard ratio
(95% CI)
P value
Hormone receptor (HR2) status 0.59 (0.42, 0.81) 0.002
HR+ vs. HR-, 1–5 yrs after diagnosis
HR+ vs. HR-, 6–10 yrs after diagnosis 0.97 (0.59, 1.62) 0.92
Age at diagnosis (years)
≥40 vs. <40 0.69 (0.49, 0.96) 0.03
Nodal status
Negative vs. positive 0.62 (0.45, 0.87) 0.006
Stage
T1 N0 vs. other 0.58 (0.33, 1.0) 0.05
Prior chemotherapy1
Anthracycline versus no anthracycline 0.78 (0.38, 1.61) 0.51
Anthracycline + taxane versus
anthracycline alone
0.85 (0.64, 1.14) 0.27
1Separate models, each including all other prognostic factors, were used to
estimate the hazard ratio for anthracycline versus no anthracycline and
anthracycline with taxane versus anthracycline alone; 2HR+ = ER+ or PR+;
HR- = ER- and PR-. The hazard ratio estimate for each prognostic factor is
adjusted for all other factors listed in the table. HER2+, human epidermal
growth factor receptor 2 positive; TEACH, Tykerb evaluation after chemotherapy;
CI, confidence interval.
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response to certain chemotherapies, including anthracy-
clines and taxanes [16,17]. Comparison of the risk of re-
currence by adjuvant chemotherapy (univariable and
multivariable analyses) in our cohort did not show a de-
crease in risk by adding taxanes in the absence of anti-
HER2 therapy. However, these results might be biased by
underlying differences in risk, as we were not able to
analyze reasons for including or excluding taxanes in the
treatment of our patients.
Limitations of our analyses include our inability to col-
lect (competing) causes of death so that we are not able
to provide overall survival data for our cohort. As sur-
vival post progression is expected to be very long in this
cohort of patients, the TEACH trial focused on PFS as a
primary endpoint as do all adjuvant BC trials. Overall
survival data are not uniformly available within these
trials in patients experiencing a recurrence. As cost-
effectiveness analyses are typically based on ‘quality-
adjusted life years gained’, information on overall survival,
ideally by age and comorbidities, would have been the
preferable outcome measure as a basis for treatment deci-
sions in health care settings with limited resources. In
addition, not all HER2+ BC patients are represented in
this analysis, as, similar to the large adjuvant trastuzumab
trials [13,18,19], patients with small, low-risk tumors were
not included in TEACH. However, even if absolute risksand benefits are smaller in low-risk tumors, we assume
that our main findings, including the difference in the be-
havior of recurrence between HER2+HR+ and HER2+
HR- tumors, hold true in biologically similar, lower risk
situations.
Overall our results show an ongoing risk of recurrence
in HER2+ BC patients, not treated with anti-HER2 ther-
apy over 10 years. The reported time-varying hazard
functions by HR status will allow up-to-date estimates of
absolute treatment effects in these patients and might
serve as ‘historical’ control for further analyses of other
novel interventions being considered. Based on the adju-
vant data of trastuzumab in HER2+ early BC, health care
providers should strive to ultimately provide trastuzumab
to all eligible patients. However, in health care settings
where approval of expensive drugs along the lines of first-
world scenarios is not affordable, knowledge about the
high risk of recurrence in HER2+HR- patients might help
to devise subgroup-specific surveillance or anti-HER2
treatment strategies in this circumstance.Conclusions
Outcomes in patients with HER2+ early BC not receiv-
ing anti-HER2 therapy strongly depend on HR expres-
sion. The mean hazard of recurrence in years 1 to 5 post
diagnosis in HER2+ HR- compared to HER2+ HR+ pa-
tients is 9 vs. 5%/year (hazard ratio 0.59, P = 0.002). This
finding is particularly relevant in health care settings
with limited access to adjuvant anti-HER2 treatment.Additional file
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